

Steering Committee Monday, June 10, 2024 2:30pm ET



Agenda for June 10, 2024

Time	Topic	Speaker(s)
2:30 – 2:35pm ET	Welcome and Announcements	Michael Kurilla Ruth O'Hara
2:35 – 2:45pm ET	Report Out: TS-CBA Working Group	Wayne McCormack
2:45 – 2:55pm ET	Discussion/Q & A	
2:55 – 3:05pm ET	Fall Meeting Logistics Update	Kerry James
3:05 – 3:20pm ET	TIN Update	Daniel Ford
3:20 – 3:30pm ET	Discussion/Q & A	
3:30pm ET	Adjourn	



Welcome and Announcements

Michael Kurilla Ruth O'Hara



Development of a Translational Science Competency-Based **Mentoring Tool**



Wayne T. McCormack, PhD
on behalf of the Translational Science
Competency-Based Assessment Working Group





Value of Using a Translational Science Competency-Based Mentoring Tool


Inform Trainees & Scholars about expectations

 Tool for self-assessment and self-directed learning throughout training and future research careers

Tool for mentor assessment of training progress

Support productive mentoring conversations

 Combined with curricular mapping and program enhancement plans, provide a framework for continuous improvement of learning objectives, training, and assessment



Translational Science Competency-Based Assessment Working Group

Chair: Wayne T. McCormack, PhD (UF)

Roster: 54 members from 29 CTSA hubs

Boston U Oregon HSU U Massachusetts

Clemson U Penn State U U Michigan Duke U Rutgers U U Minnesota

Einstein Stanford U U North Carolina

Georgetown U U Arkansas Med Sci U Rochester

Howard U U Buffalo U Texas Austin

Mayo Clinic U Cincinnati U Texas HSC San Antonio

Med Coll Wisconsin U Colorado U Washington NYU U Florida U Wisconsin

Ohio State U U Kansas Virginia Commonwealth U

CTSA Roles: K, T, WD, Evaluation, Team Science, Pilot Studies

Meetings: 1st and 3rd Wednesday at 1:00 pm (ET)

Milestone Approach: Learning Is a Developmental Process

- Milestones: expectations for the knowledge, skills and attitudes at stages of development, demonstrated by observable behaviors
 - Verderame et al., 2018. Competency-based assessment for the training of PhD students and early-career scientists. eLife 7:e34801


Dreyfus &	Novice	Advanced Beginner	Competent	Proficient	Expert
Dreyfus Levels of Skill Acquisition	Rule-based behavior, limited, inflexible	Incorporates aspects of the situation	Acts consciously from long-term goals and plans	Sees situation as a whole and acts from personal conviction	Has intuitive understanding of situations, zooms in on central aspects
Translational Scientist Training Stages	Beginning PhD Student / Clinician beginning research training with little or no experience	Advanced PhD Student / Clinician Scientist during early research training	Defending PhD Student / Beginning Postdoctoral / Clinician Scientist during later research training	Postdoctoral Trainee / Early Career Scientist / Clin Sci near end of research training / Residents/Fellows	Science Professional / Research Team Leaders (may be Aspirational)

Milestone Approach: Learning Is a Developmental Process

- Milestones: expectations for the knowledge, skills and attitudes at stages of development, demonstrated by observable behaviors
 - Verderame et al., 2018. Competency-based assessment for the training of PhD students and early-career scientists. eLife 7:e34801

Dreyfus &	Novice	Advanced Beginner	anced Beginner Competent		Expert
Dreyfus Levels of Skill Acquisition	Rule-based behavior, limited, inflexible	Incorporates aspects of the situation	Acts consciously from long-term goals and plans	Sees situation as a whole and acts from personal conviction	Has intuitive understanding of situations, zooms in on central aspects
Translational Scientist Training Stages	Beginning PhD Student / Clinician beginning research training with little or no experience	Advanced PhD Student / Clinician Scientist during early research training	Defending PhD Student / Beginning Postdoctoral / Clinician Scientist during later research training	Postdoctoral Trainee / Early Career Scientist / Clin Sci near end of research training / Residents/Fellows	Science Professional / Research Team Leaders (may be Aspirational)
	MILESTONES				
Observable Behaviors	discuss, describe, follow	identify, use, explain	design, develop, evaluate	plan, adjust, teach	lead, review, mentor

Proposed Process for Mentor & Self-Assessment



Characteristics of a Translational Scientist

CHARACTERISTICS OF A TRANSLATIONAL SCIENTIST

Translation is the process of turning observations in the laboratory, clinic and community into interventions that improve the health of individuals and the public - from diagnostics and therapeutics to medical procedures and behavioral changes. The professionals involved in this process, either developing interventions or improving the process itself, are TRANSLATIONAL SCIENTISTS.

RIGOROUS RESEARCHER

Conducts research at the highest levels of rigor and transparency, possesses strong statistical analysis skills, and designs research projects to maximize reproducibility.

BOUNDARY CROSSER

Breaks down disciplinary silos and collaborates with others across research areas and professions to collectively advance the development of a medical intervention.

TEAM PLAYER

Practices a team science approach by leveraging the strengths and expertise and valuing the contributions of all players on the translational science team.

PROCESS INNOVATOR

Seeks to better understand the scientific and operational principles underlying the translational process, and innovates to overcome bottlenecks and accelerate that process.

DOMAIN EXPERT

Possesses deep disciplinary knowledge and expertise within one or more of the domains of the translational science spectrum ranging from basic to clinical to public health research and domains in between.

SKILLED COMMUNICATOR

Communicates with understanding with all stakeholders in the translational process across diverse social, cultural, economic and scientific backgrounds, including patients and community members.

SYSTEMS THINKER

Evaluates the complex external forces, interactions and relationships impacting the development of medical interventions, including patient needs and preferences, regulatory requirements, current standards of care, and market and business demands.

Gilliland et al., 2019, The Fundamental Characteristics of a Translational Scientist, ACS Pharmacol Transl Sci. 2(3):213-216

Faupel-Badger et al., 2022. Advancing translational science education. Clin Transl Sci. 15(11):2555-2566











TRANSLATIONAL SCIENCE PRINCIPLES

Scientific and Operational Approaches to Advance Translation









Phase 1: Develop list of competency domains & competencies

Finalize the list of domains and competencies

Do we have the right list of competencies? Is anything important missing?

Use feedback from trainees and mentors (via survey) to finalize the competencies



Process Innovator Systems Thinker

Domain Expert
Boundary Crosser
Team Player
Skilled Communicator
Rigorous Researcher

Ethical Researcher Resilient Scientist Research Leader

Point of View: Competency-based assessment for the training of PhD students and early-career scientists

Michael F Verderame [™], Victoria H Freedman, Lisa M Kozlowski, Wayne T McCormack

46 Translational Science Competencies

PROCESS INNOVATOR

- A. Focus on unmet needs
- B. Use creativity & innovation
- C. Seek efficiency & speed
- D. Find generalizable & impactful solutions

SYSTEMS THINKER

- A. Operate within a system of therapeutic innovation
- B. Leverage interconnections of translational research
- C. Integrate patient perspectives

RIGOROUS RESEARCHER

- A. Recognize important questions
- B. Design and execute experimental/study protocols
- C. Interpret data & troubleshoot technical issues
- D. Design & manage a research program
- E. Apply basic statistical analysis methods
- F. Use appropriate informatics methods
- G. Manage research data
- H. Conduct research according to lab safety & regulatory policies

DOMAIN EXPERT

- A. Use historical context of a specific area
- B. Use current content expertise in the specific area
- C. Use tools and approaches for the specific area

BOUNDARY CROSSER

- A. Use knowledge from multiple disciplines
- B. Use broad scientific approaches
- C. Participate across translational phases
- D. Engage stakeholders across professions
- E. Engage with communities

TEAM PLAYER

- A. Demonstrate a cross-disciplinary, collaborative mindset
- B. Demonstrate reflective awareness in a team environment
- C. Apply strategies to work effectively within diverse teams

SKILLED COMMUNICATOR

- A. Practice effective oral presentation skills
- B. Write and review scientific manuscripts for publication
- C. Write and submit research grant proposals
- D. Communicate effectively with patients & community members
- E. Communicate effectively with funders
- F. Communicate effectively with policy-makers

ETHICAL RESEARCHER

- A. Practice responsible conduct of research (RCR)
- B. Apply ethical decision-making in RCR
- C. Display moral courage and research integrity

RESILIENT SCIENTIST

- A. Motivate self and others
- B. Demonstrate perseverance
- C. Adapt to new situations & challenges
- D. Seek professional growth opportunities
- E. Build professional network

RESEARCH LEADER

- A. Develop an Inclusive and Shared Vision
- B. Foster integration and a collaborative environment
- C. Practices effective organization and planning skills
- D. Empower progressive decision making
- E. Facilitate collaborative problem-solving
- F. Promote a culture of trust and psychological safety

Phase 1: Develop list of competency domains & competencies

Finalize the list of domains and competencies

Do we have the right list of competencies?
Is anything important missing?

Use feedback from trainees and mentors (via survey) to finalize the competencies

- For competencies in each domain:
 - include the competency as written
 - revise as suggested in comments
 - omit the competency because it does not fit the domain
- Are any competencies missing?

- 181 responses
 - 58 CTSA hubs represented

T Trainees & K Scholars	34%
T/K Program Directors	25%
Other WD Roles	24%
Other	18%

Phase 1: Develop list of competency domains & competencies

Finalize the list of domains and competencies

Do we have the right list of competencies? Is anything important missing?

Use feedback from trainees and mentors (via survey) to finalize the competencies

Deliverable 1: TS Competency Framework

Phase 2: Calibrate the milestones for competency levels

Write milestones for each competency at five levels of skill acquisition, aligned with training stages

Are the milestones calibrated correctly? Pilot-test with trainees all levels Fall 2024

Revise based on pilot-test results and feedback from trainees & scholars

Predoctoral T Trainees K Scholars

DOMAIN EXPERT

- A. Use historical context of a specific area
- B. Use current content expertise ...
- C. Use tools and approaches ...

00000

0 1 2 3 4 5

00000 00000

Postdoctoral T Trainees

Phase 1: Develop list of competency domains & competencies

Finalize the list of domains and competencies

Do we have the right list of competencies? Is anything important missing?

Use feedback from trainees and mentors (via survey) to finalize the competencies

Deliverable 1: TS Competency Framework

Phase 2: Calibrate the milestones for competency levels

Write milestones for each competency at five levels of skill acquisition, aligned with training stages

Are the milestones calibrated correctly?
Pilot-test with trainees all levels

Revise based on pilot-test results and feedback from trainees & scholars

Phase 3: Pilot-test the final TS-CBA tool

Compare self/mentor assessment; Survey users about usability, feasibility, utility; Focus groups with trainees, scholars & mentors (mentoring value)

Spring 2025

Final revisions

Deliverable 2:

Publish TS-CBA tool
and outcomes

Discussion

- Is the progress satisfactory to date?
- Are we on the right track to make an impact with this WG?
- Are we engaging appropriate stakeholders/participants?
- Are there other desirable goals or deliverables that may enhance impact?
- Suggestions about enhancing implementation and dissemination?



Fall Meeting Logistics

Kerry James



2024 Fall Planning Committee (FPC)

VOLUNTEERS

Theodore Wun, FPC Co-chair, UC Davis

Daniel Ford, Johns Hopkins University

Daniel Foster, University of Colorado Anschutz Medical Campus

Tesheia Johnson, Yale University

Jessica Kahn, University of Cincinnati – Cincinnati's Children's

Mimi Kim, Albert Einstein School of Medicine

Grace McComsey, Case Western University

Jareen Meinzen-Derr, University of Cincinnati - Cincinnati Children's

Andriana Morales Gomez, Mayo Clinic

Doris Rubio, University of Pittsburgh

Kathryn Sandberg, Georgetown University

Ronald Sokol, Children's Hospital Colorado

Gelise Thomas, Case Western University

NCATS

Michael Kurilla, FPC Co-chair

Erica Rosemond

Heather Baker

Jennie Conroy

CCOS

Lauren Fitzharris, Logistics Lead

Kerry James, Project Manager

Cindy Mark, Senior Meeting Coordinator

*Amanda Scott, Lead Meeting Planner

*Questions for FPC?

Contact FallMtg@ccos.ctsa.io



Fall Planning Committee

- Started meeting on April 23, 2024
- Meeting on the 2nd and 4th Tues at 1-2pm ET

2024 Fall CTSA Program Meeting Goals

Meeting Goals: To provide Hub leadership with an opportunity to:

- Network with their peers
- Share best practices for practical applications
- Gain knowledge through resource updates



Fall 2024 CTSA Program Meeting

Building CTSA Program Impact through Innovation, Collaboration and Equity

DATE: November 13-15th

LOCATION: Bethesda North Marriott

Day 1:

- TIN Meeting
- CTSA Administrators Meeting
- CTSA Steering Committee Meeting

Days 2 (full day) and 3 (half day):

CTSA Program Meeting

More details and online registration to come!

Questions?

Contact FallMtg@ccos.ctsa.io



2024 Fall Program Meeting – Session Topic Ideas

Broad Topic	Ideas from Steering Committee, Pods, DCI
Translational Science	 Translational scientist competencies, continuity, and next steps (a panel presentation) Careers in translational science Senior investigators describe what it is like to have funding, continue their research, and make meaningful contributions PI succession planning (Have senior PI talk about success) Accomplishments of new investigators could be celebrated Early career scholars (rather than more senior investigators) talk about their journeys toward promotion, the resources they used, and how the CTSA program supported them Outcomes of scholars trained with new programs that focused on translational science Funding for translational science outside of NCATS Catalyzing translational science innovations at hubs and engaging commercial entities and business schools NIH and hub experience re: new FOA
NCATS Strategic Plan	 Session could be interactive and include ideas for implementing the plan Provide opportunity for hubs to provide input Session with the new NIH Director to hear her vision for CTSAs
Clinical Trials	 Enhancing diversity in clinical trials Enhancing the impact of clinical trials Novel and adaptive trial designs that could accelerate clinical trial research

2024 Fall Program Meeting – Session Topic Ideas

Broad Topic	Ideas from Steering Committee, Pods, DCI
CTSA Program Updates / Issues	 Revisit the updates from TIN, WGs, ENACT, Enterprise Committees, Collaboration grants to ensure hub engagement Opportunities for collaboration across the networks Onboarding of new PIs (Targeted programming for "new" CTSA Directors and Associate Directors (i.e. 1-3 years)) Retaining research staff (e.g., biostatisticians, technicians, research administrators) Issues related to the cost/expense of clinical and translational research R03 session
Emerging Health Threats	Climate Change and Health
Dissemination and Implementation Science	 Advancing D&I science Plan for the CTSA consortium? Opportunity to provide hub feedback
Data Platforms	N3C present and future
2023 Fall Meeting Topics (e.g., AI, RWD/RWE)	 Revisit topics from 2023 with focus on how CTSAs contribute (e.g., Discuss AI and ARPA-H next steps with a greater CTSA focus) Rigor and reproducibility in RWD/RWE
New network for research and primary care	 Network is in development, but more information will be available in the Fall Could include lessons learned from the primary care practice-based research networks (PBRNs)
Evaluation	 Consortium Level Evaluation The future of Metrics with the TSBM model

Draft Agenda


Thursday, Nove	mber 14, 2024			
8:30 AM	9:45 AM	Session 1: Welcome & Keynote		
9:45 AM	10:00 AM	Break		
10:00 AM	11:30 AM	Session 2: CTSA Collaborations with Primary Care Practice-Based Research Networks (PBRNs)		
11:30 AM	12:15 PM	Poster Session A		
12:15 PM	1:45 PM	Lunch Break		
1:45 PM	3:15 PM	Session 3: PCORNnet/CTSA Collaborations Innovations from TIN, ENACT, N3C to Ensure Hub Engagement		
3:15 PM	3:30 PM	Break		
3:30 PM	4:15 PM	Poster Session B		
4:15 PM	5:45 PM	Session 4: Women's Health Initiative DEI in Clinical Trials		
Friday, Novemb	er 15, 2024			
8:00 AM	9:15 AM	Session 5: CTSA Experiences with Transition from Translational Research to Translational Science Engagement across Communities		
9:15 AM	9:30 AM	Break		
9:30 AM	10:45 AM	Session 6: Application of Generative AI and Large Language Models in Translational Science: Best Practices for Clinical Decision Making and Equity		
10:45 AM	11:00 AM	Break		
11:00 AM	12:30 PM	Session 7: NCATS Session		
12:30 PM	1:00 PM	Closing		

Session Leader Responsibilities

Session Leader(s)

- Design 90-minute session structure
- Provide updates on session development during these calls
- Identify and invite speakers
- Submit initial session agenda including proposed speakers and contact information
- Confirm speakers by deadline
- Submit final session agenda
- Facilitate session including speaker introductions, panel discussions, audience interactions and/or additional incorporated session activities.
- Have the expertise and equipment on-hand to successfully perform/troubleshoot any demonstrations that you plan





Planning Timeline for Fall Meeting – Nov 13-15, 2024

By May 31

Finalize Fall Meeting theme and topics

 Begin promotional activities

By Jun 30

By Jul 31

By Aug 31

By Sep 30

By Oct 15

- Confirm Session Leads
- Initial session agendas due
- Determine Poster Session theme and structure
- Discuss suggested speakers
- Registration opens

- Confirm and promote speakers
- Finalize Fall Program flow and agenda
- Final session agendas due
- Poster submissions due
- Registration closes

Trial Innovation Network (TIN)






TIN Update


- Current TIN activity with consultations
- Expansion of CTSA Hubs in TIN
- Steering Committee support for TIN surveys
- TIN CTSA PIs "Advisory Committee"
- TIN Role in "Care for Health" NIH Primary Care Research Initiative





Reporting of the TIN efforts to date





Select NIH ICs Engaged with the TIN

- NHLBI-80 studies
- National Heart, Lung, and Blood Institute
- NINDS-35 studies
- National Institute of Neurological Disorders and Stroke
- NIDDK-31 studies
- National Institute of Diabetes and Digestive and Kidney Diseases

- NCATS-30 studies NIH
- National Center for Advancing Translational Sciences
- NICHD-26 studies
- Eunice Kennedy Shriver National Institute of Child Health and Human Development
 - NIA-19- studies



Use Cases from the RIC





TARGET: Initial consultation + Resources

 Overview: Treatments Against RA and Effect on FDG PET-CT (TARGET) examined the effect of RA disease modifying drugs on vascular inflammation; recruitment goals of 400 participants across 40 sites

Resources included

- recruitment materials,
- recruitment feasibility assessment
- Clinician Study App (CSA)
- Competing Studies Tool (CTT)
- Social Media guidance

Outcomes:

- Completed enrollment within timeframe
- Became a repeat customer for a new grant submission

Did You Know?

- Rheumatoid arthritis patients have an increased risk of heart attacks and strokes.
- Traditional tools used to predict risk of heart disease do not apply well to rheumatoid arthritis patients
- Your arthritis medications could lower this risk.

Medical care only improves with the help of volunteers like you. Your participation can help improve the treatment and outcomes of future rheumatoid arthritis patients.



To learn more about the TARGET study, please call:

Kathleen Vanni kvanni@bwh.harvard.edu 617-525-7716

Fengxin Lu FLu1@bwh.harvard.edu 617-525-8786

Or visit us online: www.targetra.org

Funded by:





Join us in the fight to prevent heart disease in Rheumatoid Arthritis patients







LUNA: Initial consultation + Resources

- Overview: Smoking cessation study within a lung cancer screening program; actively recruiting but looking for more effective and sustainable methods
- Received recommendations report + 2 resources: 1) Social Media campaign, and 2) Community Engagement Studio
- Outcomes: Uptick in enrollment after social media campaign; successful completion of enrollment; published manuscript



Contemporary Clinical Trials



Volume 107, August 2021, 106461

Short Communication

Engaging smokers in research: Utility of Facebook in facilitating recruitment to a smoking cessation study


Sarah K. Cook ^a $\stackrel{\bowtie}{\sim}$ $\stackrel{\bowtie}{\sim}$, Rebecca N. Jerome ^a, Julia Dunagan ^a, Nan Kennedy ^a, Terri Edwards ^a, Jennifer A. Minnix ^b, Leann Witmer ^b, Jennifer Ferguson ^b, Paul Cinciripini ^b, Consuelo Wilkins ^{a, c, d, f}, Paul Harris ^{a, e}

Conclusions

The social media campaign was successful at increasing outreach and interest in the LUNA study. However, the price-per-participant enrolled was higher than in comparable tobacco cessation studies. These results and lessons learned may be beneficial to others considering social media as a recruitment method for their clinical research trial.



TIN Cycle 2-Expanded Partnerships







TIN Cycle 2

40 new submissions



20 different Organization/ Institutions



3 New Organizations/ Institutions

Boston University	Stanford University	University of Michigan	Weill Cornell Medical College/ Hunter College
Columbia University	University of Utah	University of Minnesota	University of Missouri
Duke University	Ohio State University	University of Rochester	University of Arizona
Icahn School of Medicine at Mount Sinai	University of Pittsburgh	University of Wisconsin-Madison	The Alzheimer's Association
Johns Hopkins University	University of Colorado	Vanderbilt University Medical Center/ Meharry Medical Center	Neurona Therapuetics (UC collaboration)
THIAL IIII VAIIO	VIVE IVO		Science Awards Program

TIN Survey Process

NCATS CTSA Program Policy and Procedures for Surveys

A Federal agency cannot collect *or sponsor a collection of information* from 10 or more public respondents without obtaining approval from the Office of Management and Budget (*Paperwork Reduction Act (PRA) 1995*)

When making determinations to assess whether the project, in question, is subject to PRA clearance, NIH needs an answer to the following questions:


- 1. Will the program analyze the project outcomes in a systematic way?
- 2. Will the program publicize the results of your systematic analyses?

If the answer to both questions is yes, then the program is conducting NIH research and will be considered exempt from the PRA approval requirements as outlined by the 21st Century Cures Act.

An example of an item that is exempt from PRA approval includes the following:

 Customer Satisfaction / Feedback Surveys if outcomes are analyzed in a systematic way and the results are publicized.

NCATS CTSA Program Policy and Procedures for Surveys 11/22/2017 TRIAL INNOVATION NETWOR





Survey Request
Intake and
Prioritization
Section 4.3



Obtain Approval
Section 4.4



Survey request and approval process



Section 4.7



Distribute survey to target audience
Section 4.6



Develop survey (including pretesting)

Section 4.5



Conduct analysis
Section 4.8



Disseminate results
Section 4.9



Submit final survey to CCOS archive

Section 4.10

NCA



Table 1. CTSA Survey Approval Process by Survey Type

Survey	Target	Reviewed by	Approved by	Distribution	
Source					
	EC (Including those developed by work groups)	Lead Team of the EC & NCATS Program COR	EC NCATS Program Officer	CCOS Survey Team (will	
A. EC Survey	Other ECs	Lead Team of the Other ECs & NCATS Program COR	EC NCATS Program Officer	support up to 3 survey per EC, per year)	
		CTSA Program Steering	Leadership of the		
	CTSA Program Pls	Committee &	Division of Clinical		
		NCATS Program COR	Innovation, NCATS		
B. CTSA Program Consortium Grantos (not	CTSA Program (Described in Grant Application)	CTSA Program Steering Committee & NCATS Program COR	N/A	CCOS Survey Team	
Grantee (not Hub) Survey	CTSA Program (Not Described in Grant Application)	CTSA Program Steering Committee & NCATS Program COR	Leadership of the Division of Clinical Innovation, NCATS	CCOS Survey Team	
C. CTSA Program Hub or Partner Survey	CTSA Program Hubs	CTSA Program Steering Committee & NCATS Program COR	Leadership of the Division of Clinical Innovation, NCATS	CCOS Survey Team	
D. Other CTSA groups (Admin,	Within CTSA Program groups (e.g.,			The group specific to th	
Communicators,	Administrators,	Self-reviewed &	Self-approved	The group specific to the	

Training Academy Vision

- The TIN is developing a training program designed to address these gaps in critical competencies necessary for engaging in and managing multicenter clinical trial activities.
- We envision a program that extends beyond the mandatory training in institutional Human Subjects Research (HSR) and Good Clinical Practice (GCP).
- Our target audience will be investigators and clinical research managers transitioning from single-site to multicenter clinical trials.





The Five Phases of a Multicenter Clinical Trial

Planning and Development

Trial procedures are operationalized, the data, statistics, regulatory, safety and management teams are assembled, participating centers are identified, data collection systems are set up, and supporting study documents and diversity plans are developed.

Phase 1

Phase 2

Startup

Study documents are shared with participating centers, and regulatory approvals are obtained. Data collection systems and collaboration platforms are deployed. Participating centers are trained and activated, oversight committees conduct initial meetings, and study enrollment opens.

Implementation

Trial is conducted as per the established protocols, with patient recruitment, data collection, and monitoring of study participants. Focus shifts to monitoring site performance, regulatory compliance, endpoint collection, continued training, and QA/QC/monitoring

Phase 3

Phase 4

Closeout

Participant enrollment is complete, data is collected and cleaned, data collection systems are locked, trial regulatory reports are compiled, regulatory and contractual responsibilities are completed, and sites are closed.

Data Analysis and

Dissemination
Cleaned data is
analyzed, conclusions
are drawn, leading to
publication in scientific
journals or presentation
at conferences. Findings
are disseminated to
participants and to the
scientific and medical
communities to further
inform clinical research
and practice.

Phase 5

Fashioned from original art by Caroline Foley, University of Utah, for Lane, K., Palm, M., Marion, E., Kay, M., Thompson, D., Stroud, M.,... Ford, D. (2023). Approaches for enhancing the informativeness and quality of clinical trials: Innovations and principles for implementing multicenter trials from the Trial Innovation Network. Journal of Clinical and Translational Science, 7(1), E131, doi:10.1017/cts.2023.560

The Five Phases of a Multicenter Clinical Trial

Planning and Development

Trial procedures are operationalized, the data, statistics, regulatory, safety and management teams are assembled, participating centers are identified, data collection systems are set up, and supporting study documents and diversity plans are developed.

Phase 1

Phase 2

Startup

Study documents are shared with participating centers, and regulatory approvals are obtained. Data collection systems and collaboration platforms are deployed. Participating centers are trained and activated, oversight committees conduct initial meetings, and study enrollment opens.

Implementation

Trial is conducted as per the established protocols, with patient recruitment, data collection, and monitoring of study participants. Focus shifts to monitoring site performance, regulatory compliance, endpoint collection, continued training, and QA/QC/monitoring

Phase 3

Phase 4

Closeout

Participant enrollment is complete, data is collected and cleaned, data collection systems are locked, trial regulatory reports are compiled, regulatory and contractual responsibilities are completed, and sites are closed.

Data Analysis and

Dissemination
Cleaned data is
analyzed, conclusions
are drawn, leading to
publication in scientific
journals or presentation
at conferences. Findings
are disseminated to
participants and to the
scientific and medical
communities to further
inform clinical research
and practice.

Phase 5

Fashioned from original art by Caroline Foley, University of Utah, for Lane, K., Palm, M., Marion, E., Kay, M., Thompson, D., Stroud, M.,... Ford, D. (2023). Approaches for enhancing the informativeness and quality of clinical trials: Innovations and principles for implementing multicenter trials from the Trial Innovation Network. Journal of Clinical and Translational Science, 7(1), E131, doi:10.1017/cts.2023.560

Survey Respondent Profile

- 283 respondents partially or fully completed the survey
- 77% (n=218) identified themselves as Pls/Clinical research managers
- Other roles 23%

#	Field	Choice Count	
1	Research Coordinator	28.13%	18
2	Clinical Research Manager (CRM)/Trial Manager/Project Manager	4.69%	3
3	CTSA PI	4.69%	3
4	CTSA Medical Director	0.00%	0
5	CTSA Point of Contact	15.63%	10
6	CTSA Biostatistician	0.00%	0
7	Other	46.88%	30
			64





Survey Respondent Profile

- 283 respondents partially or fully completed the survey
- 77% (n=218) identified themselves as Pls/Clinical research managers
- Other roles 23%

#	Field	Choice Count	
1	Research Coordinator	28.13%	18
2	Clinical Research Manager (CRM)/Trial Manager/Project Manager	4.69%	3
3	CTSA PI	4.69%	3
4	CTSA Medical Director	0.00%	0
5	CTSA Point of Contact	15.63%	10
6	CTSA Biostatistician	0.00%	0
7	Other	46.88%	30
			64





Ranking & Comparison

1 No need 2 Low priority 3 Moderat e Need



			Other	Top 5	All Other
# Training Academy Module		PIs & RMs	Roles	Sites	Sites
	N=283		N=65		
	(100%)	(77.03%)	(22.97%)	N=5	N=29
1 Multicenter Clinical Trial - Planning and Development	3.26	3.21	3.44	3.15	3.38
2 Accelerated Site Start-up	3.19	3.22	3.11	3.06	3.32
3 Managing Sites in a Multisite Clinical Trial	3.14	3.12	3.2	3.04	3.25
4 Multicenter Clinical Trial Management - Bringing It All Together	3.14	3.17	3.05	3.06	3.22
5 Multicenter sIRB Procedures and Coordination	3.12	3.12	3.14	3.03	3.21
6 Recruitment and Retention in Clinical Trials	3.09	3.08	3.11	3.04	3.14
7 Diversity in Clinical Trials	3.05	3.04	3.11	2.97	3.14
8 Enhancing Clinical Trial Quality through Monitoring Plans and Quality Assurance	3.03	3.02	3.09	2.87	3.2
Understanding Clinical Trial FDA Submissions and Navigating FDA Oversight in					
9 Clinical Trials	3.01	3.02	2.96	2.9	3.13
10 Developing Electronic Data Capturing (EDC) Systems	2.91	2.94	2.78	2.9	2.92
11 Adverse Event (AE) Documentation and Reporting		2.85	3.07	2.84	2.94
12 Developing Electronic Trial Master Files (eTMF)	2.86	2.89	2.73	2.83	2.89
13 Data and Safety Monitoring Board (DSMB) Management	2.8	2.8	2.82	2.74	2.86
14 Multisite Study Closure Procedures		2.77	2.74	2.69	2.86
15 Statistical Analysis Plan Development and Compliance	2.65	2.63	2.69	2.61	2.7
16 Data Analysis and Dissemination	2.58	2.59	2.59	2.47	2.7
17 Science Communication and Public Relations	2.55	2.57	2.48	2.45	2.65

TIN CTSA Hub PI Advisory Committee

- Pls or TIN Medical Directors or Designee?
- Communication back to your CTSA Hub?
- Most helpful advice?





NIH Director Care for Health Initiative

- Connecting Research to Primary Care Sites to Expand Diversity
- Network of Networks Concept
- Initial goal is expanding enrollment of existing NIH studies into rural areas
 - Sally Hodder Mountaineer Health Initiative with Johns Hopkins TIC
- Programs in Network Research Hub
 - Clinical Science Center study design?
 - Operations Center
 - Independent Review and Monitoring Boards
 - Community Engagement
- Industry Partnership
 TRIAL INNOVATION NETWORK







2:30-3:30pm ET

We will be discussing and voting on new working groups.



Adjourn

